Kiniksa Pharmaceuticals International (KNSA) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Kiniksa Pharmaceuticals International (KNSA) over the past year, gaining 374.5% versus a gain of 109.3%. Over five years, KNSA leads with a +596.8% price change compared with -13.4% for PRAX. Praxis Precision Medicines is the larger company by market cap ($7.26 billion vs $6.22 billion), about 1.2 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | PRAX |
|---|---|---|
| Share price | $79.78 | $259.86 |
| Market cap | $6.22B | $7.26B |
| 1-day change | +1.31% | -1.40% |
| YTD return | +93.41% | -11.83% |
| 1-year return | +109.34% | +374.54% |
| 5-year return | +596.77% | -13.42% |
| P/E ratio (TTM) | 80.59 | — |
| Forward P/E | 49.32 | — |
| EPS (TTM) | $0.99 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $0 |
| Revenue growth (YoY) | +60.09% | -100.00% |
| Net income (latest FY) | $59.01M | $-303.27M |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | — |
| Net margin | 8.71% | — |
| 52-week high | $82.94 | $392.70 |
| 52-week low | $35.20 | $50.56 |
| Distance from 52-week high | -3.81% | -33.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.84% | +147.99% |
| Average volume | 573.53K | 410.73K |
| Shares outstanding | 48.29M | 27.92M |
| Employees | 366 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed KNSA by 265.2 percentage points over the past year.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs -100.00%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
KNSA vs PRAX FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.26B compared with $6.22B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or PRAX?
PRAX returned +374.54% over the past 12 months, compared with +109.34% for KNSA (price return, excluding dividends). Past performance does not predict future results.
Are Kiniksa Pharmaceuticals International and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.